Title: Study on the effectiveness and the dosage of rhG-CSF given in accordance with the level of leukopenia after chemotherapy
Abstract:Objective To observe the effectiveness of the China-made recombinant human granulocyte colony stimulating factor(rhG-CSF) given in accordance with the level of leukopenia after chemotherapy in patient...Objective To observe the effectiveness of the China-made recombinant human granulocyte colony stimulating factor(rhG-CSF) given in accordance with the level of leukopenia after chemotherapy in patients with cancer,and to study the optimal dosage.Methods The patients with leukopenia were treated with subcutaneous injection of rhG-CSF according to the gradation of myelosuppression. Grade Ⅰ:75 μg;grade Ⅱ:75-150 μg;grade Ⅲ:150-225 μg;grade Ⅳ:225-300 μg.Medication was stopped when the white blood cell count reached 4.0×109/L.Results Sixty-six patients were treated,of whom 58 (87.9%) were obviously effective and 8 (12.1%) were effective,with overall effective rate of 100%.The average white blood cell count was 2.53×109/L before treatment,while it reached 9.08×109/L after treatment(P0.01).The average neutrophilic granulocyte count was 1.55×109/L before treatment and was 7.15×109/L after treatment (P0.01).The dose and days for the white blood cell to reach 4.0×109/L were grade Ⅰ:94.45μg/case,1.18 days;grade Ⅱ:196.88 μg /case,1.69 days;grade Ⅲ:693.75μg /case,5.25 days;grade Ⅳ:975.0μg /case,5.50days,respectively.Conclusions The China-made rhG-CSF is effective and has few side-effects in the patients with leukopenia after different chemotherapy.When the dosage is increased gradually according to the degree of decrease in white blood cell count,the dosage is not great,the course of treatment is short,and the cost is less than the imported products of the same kind.The treatment is worthy of further study.Read More
Publication Year: 2007
Publication Date: 2007-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot